New Drugs for Breast Cancer

The kinase inhibitor tucatinib (Tukysa) has been approved to treat advanced unresectable or metastatic HER2-positive breast cancer. The drug is given orally in combination with trastuzumab (Herceptin) and capecitabine (Xeloda). It is not first-line therapy.Sacituzumab govitecan-hziy (Trodelvy) has been approved to treat triple-negative breast cancer that has metastasized. It is a targeted therapy monoclonal antibody given by IV infusion. The drug carries a boxed warning for risk of severe neutropenia and severe diarrhea.
Source: AJN - Category: Nursing Tags: Drug Watch Source Type: research